Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Mar;21(1):8-10.
doi: 10.4104/pcrj.2012.00022.

Single inhaler maintenance and reliever therapy (SMART) in general practice asthma management: where are we?

Mike Thomas, Ian Pavord
Editorial

Single inhaler maintenance and reliever therapy (SMART) in general practice asthma management: where are we?

Mike Thomas et al. Prim Care Respir J. 2012 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Neither MT nor any member of his close family has any shares in pharmaceutical companies. In the last 3 years he has received speaker's honoraria for speaking at sponsored meetings from the following companies marketing respiratory and allergy products: AstraZeneca (AZ), Boehringer Inglehiem, (BI) GSK, MSD, Napp, Schering-Plough, Teva. He has received honoraria for attending advisory panels with; Almirall, AZ BI, Chiesi, GSK, MSD, Merck Respiratory, Schering-Plough, Teva, Novartis. He has received sponsorship to attend international scientific meetings from: GSK, MSD, AZ Mundipharma. He has received funding for research projects from: GSK, MSD, Napp. He held a research fellowship and is Chief Medical Advisor to Asthma UK. He is a member of the UK Department of Health Asthma Strategy Group and Home Oxygen Group. He is a member of the MHRA Respiratory and Allergy Expert Advisory Group. He is a member of the BTS SIGN Asthma guideline group.

In the last 3 years IDP has received speaker's honoraria for speaking at sponsored meetings from AZ, BI, GSK. He has received honoraria for attending advisory panels with; Almirall, AZ, BI GSK, MSD, Schering-Plough, Novartis, Dey, Napp. He has received sponsorship to attend international scientific meetings from BI, GSK, AZ and Napp. He is Chief Medical Advisor to Asthma UK, a member of the UK Department of Health Asthma Strategy Group and Home Oxygen Group, a member of the BTS SIGN Asthma guideline group and joint editor in chief of Thorax. Neither IDP nor any member of his family has any shares in pharmaceutical companies.

Comment on

References

    1. Demoly P, Gueron B, Annunziata K, Adamek K, Walters RD. Update on asthma control in five European countries: results of a 2008 survey. Eur Respir Rev 2010; 19(116):150–7. http://dx.doi.org/10.1183/09059180.00002110 - PMC - PubMed
    1. Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008;102(12):1681–93. - PubMed
    1. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007;29:587–95. http://dx.doi.org/10.1183/09031936.00080306 - PubMed
    1. Riemersma RA, Postma D, van der Molen T. Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Prim Care Respir J 2012;21(1):50–56. http://dx.doi.org/10.4104/pcrj.2011.00090 - PMC - PubMed
    1. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744–53. http://dx.doi.org/10.1016/S0140-6736(06)69284-2 - PubMed